<DOC>
	<DOC>NCT02586168</DOC>
	<brief_summary>The purpose of this study is to determine the effect of gemcabene on insulin sensitivity as defined by average glucose disposal rate.</brief_summary>
	<brief_title>The Effect of Gemcabene on Insulin Sensitivity in Nondiabetic Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hypersensitivity</mesh_term>
	<mesh_term>Insulin Resistance</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Good health, as determined by medical history, physical examination, EKG and clinical laboratory assessments Males; and females of non‐reproductive potential Obesity Non‐diabetic Use of any medication considered unacceptable by the clinical investigators during the 14‐day period before the start of Day 1. Hormone Replacement Therapy is acceptable. Use of a lipid‐lowering agent (niacin, fibrates, statin) during the 8 weeks before screening Use of any anti‐diabetic medications Use of any steroid medications Donation of any blood or plasma product or participation in another study in the 30 days prior to Day 1 If female, pregnant, lactating or of childbearing potential; and History of significant reaction to any fibrate lipid‐lowering agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Insulin Resistance</keyword>
	<keyword>Lipid Regulator</keyword>
</DOC>